AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 201 filers reported holding AXSOME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,640,892 | -1.9% | 80,711 | +0.9% | 0.45% | -1.3% |
| Q2 2023 | $5,748,800 | -51.8% | 80,000 | -58.6% | 0.45% | -56.7% |
| Q1 2023 | $11,922,066 | -27.5% | 193,289 | -9.4% | 1.04% | -36.0% |
| Q4 2022 | $16,450,981 | +90.1% | 213,289 | +9.9% | 1.63% | +38.6% |
| Q3 2022 | $8,656,000 | -6.8% | 194,000 | -20.0% | 1.18% | -18.7% |
| Q2 2022 | $9,288,000 | -7.5% | 242,500 | 0.0% | 1.45% | +5.1% |
| Q1 2022 | $10,037,000 | +9.6% | 242,500 | 0.0% | 1.38% | -29.5% |
| Q4 2021 | $9,162,000 | +11.2% | 242,500 | -3.0% | 1.95% | +61.5% |
| Q3 2021 | $8,240,000 | -51.1% | 250,000 | 0.0% | 1.21% | -51.5% |
| Q2 2021 | $16,865,000 | +19.1% | 250,000 | 0.0% | 2.50% | -22.6% |
| Q1 2021 | $14,155,000 | -30.5% | 250,000 | 0.0% | 3.22% | -8.2% |
| Q4 2020 | $20,368,000 | +14.3% | 250,000 | 0.0% | 3.51% | +1.5% |
| Q3 2020 | $17,813,000 | -13.4% | 250,000 | 0.0% | 3.46% | -18.8% |
| Q2 2020 | $20,570,000 | – | 250,000 | – | 4.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
| MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
| Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
| WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
| Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
| RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
| MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
| Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
| Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |